Vertex Pharmaceuticals Incorporated VRTX

526.19 3.81 0.73% as of 25 Sep
Market cap
$132.3B
P/E
30.4×
Indexes indicate stock being part of an index,
Growth Flags show if company had growth for consecutive years
Older periods Sep '25 Dec '25 Mar '26 Jun '26
ROE

+8 more TTM periods

22.31% 22.54% 24.20% 23.54%
ROA
15.60% 16.41% 17.58% 17.12%
ROIC
22.62% 21.63% 24.15% 24.09%
Return on Tangible Assets
48.87% 44.62% 45.87% 42.89%
Average Days of Receivables
60.60 62.43 59.63 61.89
Free Cash Flow per Share
13.06 12.49 14.60 14.96
Free Cash Flow
3,337.20 3,193.80 3,710.30 3,796.10
Capital Expenditures
(380.80) (437.60) (530.30) (496.80)
Piotroski F-Score
7.00 7.00 7.00 4.00
Other line items
Cash ROIC
15.75% 14.37% 15.94% 15.28%
Accounts Receivable Turnover
6.34 6.55 6.43 6.25
Accounts Payable Turnover
3.94 3.78 3.60 4.04
Inventory Turnover
1.19 1.14 1.08 1.08
Average Days of Payables
95.36 102.05 106.24 88.93
Days of Inventory on Hand
369.11 372.85 383.59 365.48
Tax Rate
(0.17) (0.15) (0.16) (0.16)
Research and Development Expense of Revenue
33.56% 32.58% 31.85% 31.04%
Selling, General and Administrative Expense of Revenue
14.02% 14.61% 15.14% 15.95%
Share Based Compensation of Revenue
5.94% 5.72% 5.62% 5.47%
Interest Coverage
0.00 0.00 0.00 0.00
Operating CF/Net income
1.01 0.92 0.98 0.97
Depreciation/Fixed assets
0.14 0.14 0.14 0.13
Capex/Depreciation
(1.90) (2.09) (2.44) (2.24)
Revenue per Share
45.87 46.94 48.08 49.61
Operating CF per Share
14.55 14.20 16.69 16.92
Capex per Share
(1.49) (1.71) (2.09) (1.96)
Capex to Sales
0.03 0.04 0.04 0.04
Net Profit Margin
31.35% 32.94% 35.51% 35.00%

Fold the line items

Columns are period end dates